28 Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology

• Joanna Roder,
• Heinrich Roder,
• Senait Asmellash,
• Minu Srivastava,
• Wei Zou,
• Mark McCleland,
• David Shames,
• Laura Maguire,
• Steven Rightmyer,
• Patrick Norman,
• Lelia Net,
• Thomas Campbell,
• Robert Georgantas

Affiliations

Joanna Roder

Aff333 Biodesix, Inc. Boulder CO USA

Heinrich Roder

Aff333 Biodesix, Inc. Boulder CO USA

Senait Asmellash

Aff347 Biodesix, Inc. Boulder CO USA

Minu Srivastava

Aff1 grid.467496.e0000000404899295Oncomed Pharmaceuticals Redwood City CA USA

Wei Zou

Department of Biostatistics Oncology, Genentech Inc, South San Francisco, California, USA

Mark McCleland

Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA

David Shames

Genentech Inc, South San Francisco, California, USA

Laura Maguire

1Biodesix, Inc., Boulder, CO, USA

Steven Rightmyer

1Biodesix, Inc., Boulder, CO, USA

Patrick Norman

1Biodesix, Inc., Boulder, CO, USA

Lelia Net

1Biodesix, Inc., Boulder, CO, USA

Thomas Campbell

1Biodesix, Inc., Boulder, CO, USA

Robert Georgantas

1Biodesix, Inc., Boulder, CO, USA